Your browser is no longer supported. Please, upgrade your browser.
Cyclerion Therapeutics, Inc.
Index- P/E- EPS (ttm)-2.00 Insider Own4.80% Shs Outstand35.71M Perf Week10.20%
Market Cap139.35M Forward P/E- EPS next Y- Insider Trans139.54% Shs Float23.72M Perf Month18.68%
Income-67.60M PEG- EPS next Q- Inst Own58.50% Short Float5.08% Perf Quarter-12.43%
Sales3.60M P/S38.71 EPS this Y43.00% Inst Trans8.59% Short Ratio1.99 Perf Half Y-8.22%
Book/sh1.83 P/B1.77 EPS next Y- ROA-64.00% Target Price- Perf Year-58.67%
Cash/sh1.64 P/C1.98 EPS next 5Y- ROE-108.80% 52W Range2.08 - 8.34 Perf YTD5.88%
Dividend- P/FCF- EPS past 5Y- ROI-129.00% 52W High-61.15% Beta-
Dividend %- Quick Ratio6.90 Sales past 5Y- Gross Margin- 52W Low55.77% ATR0.25
Employees51 Current Ratio6.90 Sales Q/Q328.60% Oper. Margin- RSI (14)53.45 Volatility9.68% 8.24%
OptionableYes Debt/Eq0.05 EPS Q/Q35.50% Profit Margin- Rel Volume1.12 Prev Close3.09
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume604.66K Price3.24
Recom3.00 SMA203.73% SMA500.90% SMA200-3.65% Volume679,704 Change4.85%
Jun-03-19Initiated Credit Suisse Neutral
Sep-08-21 08:00AM  
Aug-26-21 07:19AM  
Aug-23-21 05:00PM  
Jul-29-21 05:00PM  
Jul-22-21 04:30PM  
Jul-12-21 02:24AM  
Jul-09-21 06:14AM  
Jul-08-21 07:22PM  
Jun-04-21 10:27AM  
May-27-21 04:30PM  
May-25-21 07:00AM  
May-09-21 03:36AM  
Apr-27-21 09:00AM  
Apr-26-21 07:00AM  
Apr-21-21 07:30AM  
Apr-20-21 07:00AM  
Mar-24-21 04:05PM  
Mar-22-21 02:23AM  
Mar-19-21 07:46AM  
Mar-18-21 05:00PM  
Feb-25-21 07:00AM  
Jan-25-21 07:00AM  
Jan-21-21 12:52AM  
Jan-04-21 07:00AM  
Dec-21-20 07:30AM  
Dec-02-20 11:27PM  
Nov-15-20 07:55AM  
Nov-05-20 07:00AM  
Oct-14-20 01:09PM  
Oct-04-20 09:52AM  
Sep-04-20 07:00AM  
Aug-25-20 07:00AM  
Aug-20-20 11:01AM  
Aug-03-20 09:25AM  
Jul-30-20 09:00AM  
Jul-17-20 07:00AM  
Jul-06-20 03:17PM  
Jul-05-20 02:45PM  
Jun-18-20 04:01PM  
May-22-20 07:52AM  
Apr-10-20 07:00AM  
Mar-23-20 06:50AM  
Jan-13-20 07:00AM  
Jan-12-20 05:05PM  
Dec-24-19 08:17AM  
Dec-23-19 07:00AM  
Dec-12-19 03:43PM  
Nov-27-19 07:00AM  
Nov-01-19 10:52AM  
Oct-31-19 08:08AM  
Oct-30-19 09:24AM  
Oct-08-19 08:00AM  
Sep-25-19 01:22PM  
Sep-10-19 08:00AM  
Aug-12-19 08:00AM  
Jul-31-19 10:58AM  
Jul-24-19 03:23PM  
Jun-11-19 08:30AM  
Jun-05-19 09:50AM  
Jun-04-19 01:58PM  
May-13-19 07:00AM  
Apr-25-19 08:00AM  
Apr-09-19 05:37AM  
Apr-02-19 08:00AM  
Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of medicines for serious central nervous system (CNS) diseases. Its product candidates include CY6463, a CNS-penetrant, soluble guanylate cyclase (sGC) stimulator that is in Phase II trials for the treatment of mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS) and Alzheimer's disease with vascular pathology (ADv); Olinciguat, an orally administered vascular soluble guanylate cyclase stimulator that is in Phase II studies for the treatment of sickle cell disease (SCD); Praliciguat, an orally administered systemic sGC stimulator that is in Phase II trials for the treatment of diabetic nephropathy and heart failure with preserved ejection fraction. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
MCGUIRE TERRANCEDirectorJun 03Buy3.1296,153299,997697,313Jun 07 05:36 PM
Hecht Peter MChief Executive OfficerJun 03Buy3.28823,1702,699,9982,047,698Jun 07 05:25 PM
Slate Path Capital LP10% OwnerJun 03Buy3.12961,5382,999,9997,157,601Jun 07 04:05 PM
Hecht Peter MChief Executive OfficerMay 06Buy2.43302,000733,8601,224,528May 10 08:45 AM
Hecht Peter MChief Executive OfficerMay 05Buy2.53398,0011,006,943922,528May 06 09:27 PM
Hecht Peter MChief Executive OfficerMay 04Buy2.29300,000687,000524,527May 06 09:27 PM
Gjino AnjezaChief Financial OfficerFeb 25Sale4.001,8247,29631,599Mar 01 04:23 PM
Wright Christopher IChief Medical OfficerFeb 25Sale3.992,63710,52242,728Mar 01 04:17 PM
Currie Mark GPresident and CSODec 28Sale3.0120,10760,522251,648Dec 30 01:14 PM
Busch AndreasChief Innovation OfficerNov 09Buy2.53125,000316,250254,704Nov 12 05:05 PM
Huyett WilliamChief Financial OfficerNov 06Sale2.523,8279,64467,590Nov 10 07:07 PM